CRISPR Therapeutics AG
NASDAQ:CRSP

Watchlist Manager
CRISPR Therapeutics AG Logo
CRISPR Therapeutics AG
NASDAQ:CRSP
Watchlist
Price: 58.22 USD 1.09% Market Closed
Market Cap: 5.5B USD

Wall Street
Price Targets

CRSP Price Targets Summary
CRISPR Therapeutics AG

Wall Street analysts forecast CRSP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CRSP is 80 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

Lowest
Price Target
32.32 USD
44% Downside
Average
Price Target
80 USD
37% Upside
Highest
Price Target
281.4 USD
383% Upside
CRISPR Therapeutics AG Competitors:
Price Targets
ARX
Aroa Biosurgery Ltd
31% Upside
6990
Sichuan Kelun-Biotech Biopharmaceutical Co Ltd
30% Upside
300896
Imeik Technology Development Co Ltd
43% Upside
ORKA
Oruka Therapeutics Inc
52% Upside
2162
KeyMed Biosciences Inc
52% Upside
068270
Celltrion Inc
19% Upside
ALEC
Alector Inc
52% Upside
VTVT
vTv Therapeutics Inc
10% Upside

Revenue
Forecast

Revenue Estimate
CRISPR Therapeutics AG

For the last 9 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 79%. The projected CAGR for the next 3 years is 97%.

79%
Past Growth
97%
Estimated Growth
Estimates Accuracy
13%
Average Beat

Operating Income
Forecast

Operating Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
CRISPR Therapeutics AG

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-38%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CRSP's stock price target?
Price Target
80 USD

According to Wall Street analysts, the average 1-year price target for CRSP is 80 USD with a low forecast of 32.32 USD and a high forecast of 281.4 USD.

What is CRISPR Therapeutics AG's Revenue forecast?
Projected CAGR
97%

For the last 9 years the compound annual growth rate for CRISPR Therapeutics AG's revenue is 79%. The projected CAGR for the next 3 years is 97%.

Back to Top